Mitochondria as a target of environmental toxicants by Meyer, Joel N et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Mitochondria as a target of environmental toxicants
Meyer, Joel N; Leung, Maxwell C K; Rooney, John P; Sendoel, Ataman; Hengartner, Michael O; Kisby,
Glen E; Bess, Amanda S
Abstract: Enormous strides have recently been made in our understanding of the biology and pathobiology
of mitochondria. Many diseases have been identified as caused by mitochondrial dysfunction, and many
pharmaceuticals have been identified as previously unrecognized mitochondrial toxicants. A much smaller
but growing literature indicates that mitochondria are also targeted by environmental pollutants. We
briefly review the importance of mitochondrial function and maintenance for health based on the genetics
of mitochondrial diseases and the toxicities resulting from pharmaceutical exposure. We then discuss
how the principles of mitochondrial vulnerability illustrated by those fields might apply to environmental
contaminants, with particular attention to factors that may modulate vulnerability including genetic
differences, epigenetic interactions, tissue characteristics, and developmental stage. Finally, we review the
literature related to environmental mitochondrial toxicants, with a particular focus on those toxicants that
target mitochondrial DNA. We conclude that the fields of environmental toxicology and environmental
health should focus more strongly on mitochondria.
DOI: https://doi.org/10.1093/toxsci/kft102
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-108110
Journal Article
Published Version
Originally published at:
Meyer, Joel N; Leung, Maxwell C K; Rooney, John P; Sendoel, Ataman; Hengartner, Michael O; Kisby,
Glen E; Bess, Amanda S (2013). Mitochondria as a target of environmental toxicants. Toxicological
Sciences, 134(1):1-17.
DOI: https://doi.org/10.1093/toxsci/kft102
© The Author 2013. Published by Oxford University Press on behalf of the Society of Toxicology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),  
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use,  
please contact journals.permissions@oup.com.
Review
Mitochondria as a Target of environmental Toxicants
Joel N. Meyer,*,1 Maxwell C. K. Leung,* John P. Rooney,* Ataman Sendoel,† Michael O. Hengartner,† Glen E. Kisby,‡  
and Amanda S. Bess*
*Nicholas School of the Environment, Duke University, Durham, North Carolina; †Institute of Molecular Life Sciences, University of Zurich,  
Zurich, Switzerland; and ‡Department of Basic Medical Sciences, Western University of Health Sciences, Lebanon, Oregon
1To whom correspondence should be addressed at Nicholas School of the Environment, Duke University, Box 90328, A354 LSRC, Research Dr, Durham,  
NC 27708-0328. Fax: (919) 668-1799. E-mail: joel.meyer@duke.edu.
Received January 23, 2013; accepted April 23, 2013
Enormous strides have recently been made in our understand-
ing of the biology and pathobiology of mitochondria. Many dis-
eases have been identified as caused by mitochondrial dysfunction, 
and many pharmaceuticals have been identified as previously 
unrecognized mitochondrial toxicants. A much smaller but grow-
ing literature indicates that mitochondria are also targeted by 
environmental pollutants. We briefly review the importance of 
mitochondrial function and maintenance for health based on the 
genetics of mitochondrial diseases and the toxicities resulting from 
pharmaceutical exposure. We then discuss how the principles of 
mitochondrial vulnerability illustrated by those fields might apply 
to environmental contaminants, with particular attention to fac-
tors that may modulate vulnerability including genetic differences, 
epigenetic interactions, tissue characteristics, and developmental 
stage. Finally, we review the literature related to environmental 
mitochondrial toxicants, with a particular focus on those toxicants 
that target mitochondrial DNA. We conclude that the fields of 
environmental toxicology and environmental health should focus 
more strongly on mitochondria.
Key Words: contaminants; mitochondria; mitochondrial DNA; 
mitochondrial toxicity; mitochondrial disease.
MitochoNDriA AND MitochoNDriAl DNA
Mitochondria are essential organelles best known for ATP 
generation and their involvement in apoptosis. They also play 
critical roles in other key processes including calcium, copper, 
and iron homeostasis; heme and iron-sulfur cluster assembly; 
synthesis of pyrimidines and steroids; thermogenesis and fever 
response; and calcium signaling. The great majority of the 
~1000–1500 (Calvo and Mootha, 2010) proteins that carry out 
these functions are imported from the cytoplasm via mitochon-
dria targeting sequences or other mechanisms (Bolender et al., 
2008), and the proteins present vary significantly with tissue 
(Johnson et al., 2007). This variability probably reflects exten-
sive variability in function, ranging from energy production in 
muscle mitochondria to steroid synthesis in adrenal mitochon-
dria (Vafai and Mootha, 2012). A small number (13 in humans) 
is encoded in the mitochondrial genome, along with the tRNA 
and rRNAs required for their synthesis. These proteins are 
components of complexes I, III, IV, and V of the electron trans-
port chain (ETC). Despite their small number, they are essential 
and are transcribed at high rates: mtRNA represents ~5% of 
total cellular RNA in many tissues but as high as 30% in heart 
cells (Mercer et al., 2011).
Mitochondrial morphology also varies with cell type, 
developmental stage, and environment (Jansen and de Boer, 
1998; Rube and van der Bliek, 2004; Vafai and Mootha, 2012)
(Fig. 1). Morphology ranges from highly fragmented to highly 
networked, is regulated via the processes of mitochondrial fusion 
and fission, and is responsive to a variety of stressors (Jendrach 
et al., 2008; Twig and Shirihai, 2011). Morphological dynamics 
are critical for maintenance of mitochondrial function (Green and 
Van Houten, 2011; Youle and van der Bliek, 2012). The amount 
of cellular mitochondria and their content are regulated via 
mitochondrial biogenesis, nuclear signaling–mediated nuclear 
and mitochondrial transcription, autophagy, and intraorganellar 
degradation processes (Diaz and Moraes, 2008; Mijaljica 
et  al., 2007; Piantadosi and Suliman, 2012; Scarpulla, 2008). 
“Mitophagy” can selectively remove damaged mitochondria 
(Kim and Lemasters, 2011; Kim et  al., 2007), and damaged 
cellular components can be degraded inside the mitochondria 
or exported to lysosomes and peroxisomes via mitochondria-
derived vesicles (Fischer et al., 2012; Nunnari and Suomalainen, 
2012). Mitochondria do not merely receive instructions from the 
nucleus, however, but rather can initiate signaling in a variety 
of ways. These include “retrograde signaling” (i.e., from the 
mitochondria to the nucleus; Chae et al., 2013; Liu and Butow, 
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2006) to coordinate nuclear transcription with mitochondrial 
needs via pathways including AMP-activated protein kinase, 
sirtuins, calcium signaling, peroxisome proliferator–activated 
receptor g coactivator 1a protein, and others (Piantadosi and 
Suliman, 2012); mitochondrial-nuclear reactive oxygen species 
(ROS)–mediated signaling (Storz, 2006); cell cycle arrest 
signaling that may involve proteins with similar functions in the 
nucleus (Green et al., 2011; Koczor et al., 2009; Kulawiec et al., 
2009); and initiation of apoptosis (Tann et al., 2011; Raimundo 
et al., 2012), as opposed to the better-known amplification of 
an apoptotic process initiated elsewhere. There is evidence for 
a “mitocheckpoint” that senses mitochondrial dysfunction and 
triggers cell cycle arrest (Singh, 2006) although the mechanism 
for this response is not fully understood.
Mitochondrial DNA (mtDNA) in many animal species is a cir-
cular intron-free genome consisting of 14,000–17,000 base pairs 
(16,569 in humans) although it is much larger and noncircular and 
contains introns in some species (Anderson et al., 1981; Burger 
et al., 2003). It is typically maternally inherited and present in 
multiple copies within each cell; the mtDNAs are grouped in 
DNA-protein complexes referred to as nucleoids (Bogenhagen, 
2012; Kukat et al., 2011) that are anchored to the inner mito-
chondrial membrane. Most somatic cells in mammals have 103–
104 mtDNAs (Shoubridge and Wai, 2007), but this number varies 
significantly by cell type and developmental stage, as discussed 
at more length below. mtDNA replication occurs independently 
of the cell cycle. mtDNA half-life has been reported as 2–4 days 
(Kai et al., 2006; Lipsky and Pedersen, 1981) but has not been 
characterized in a wide range of cell types. mtDNA replication 
and transcription are regulated in part by Tfam (Mitochondrial 
transcription factor A), a major protein component of the nucle-
oid (Campbell et al., 2012). From an evolutionary perspective, 
mtDNA has a high mutation rate compared with nuclear DNA 
(nDNA). Normally, all of the mtDNAs in all of the cells of an 
organism are of the same sequence; the presence of more than 
one sequence in a cell is referred to as “heteroplasmy.”
Recognition of the key role of mtDNA integrity and mitochon-
drial function in health has grown greatly in recent years (Chan, 
2007; Chan et al., 2006; Christodoulou, 2000; Cohen, 2010; de 
Moura et al., 2010; DiMauro and Davidzon, 2005; Hirano et al., 
2001; Jansen and Burton, 2004; Kwong et al., 2006; Manfredi 
and Beal, 2000; Nunnari and Suomalainen, 2012; Schapira, 2012; 
Schmidt, 2010; Shaughnessy et al., 2010; Taylor and Turnbull, 
2005; Wallace, 2005), partly due to our increased understanding 
and awareness of mitochondrial diseases.
MitochoNDriAl DisEAsEs
mtDNA and nDNA Mutations Can Cause Mitochondrial 
Disease
Leber’s Hereditary Optical Neuropathy and mitochondrial 
myopathies were in 1988 the first diseases demonstrated to 
be caused by mtDNA mutations (Holt et  al., 1988; Wallace 
et  al., 1988). There are now more than 200, including 
MELAS (myopathy, encephalopathy, lactic acidosis, stroke-
like episodes), MERRF (myoclonus epilepsy with ragged red 
fibers), and many others (Holt, 2010). Importantly, cellular 
dysfunction and clinical disease do not occur until a threshold 
proportion of mtDNAs carrying mutations (heteroplasmy) is 
reached (DiMauro and Schon, 2003; Rossignol et al., 2003). 
Together, these diseases affect at least 1/10,000 people clinically 
(Chinnery et  al., 2012), establishing mtDNA mutations as a 
major cause of disease.
Because most mitochondrial proteins are nuclear encoded, 
it is not surprising that mutations in many nuclear genes also 
cause mitochondrial diseases. For example, mutations in 
DNA polymerase γ, the only mtDNA polymerase and thus 
Fig. 1. Mitochondrial morphology. Panel (A) shows the mitochondrial network (MitoTracker Red-stained) containing many mtDNA nucleoids (PicoGreen-
stained) surrounding the nucleus (Hoescht-stained) of a human primary fibroblast (photo: Amanda Bess). Panels (B) and (C) show a transgenic strain of C. elegans 
that expresses a mitochondrial matrix-targeted green fluorescent protein in body wall muscle cells. The image in panel (B) is from a control nematode, and the 
image in panel (C) is from a nematode exposed to 1µM carbonyl cyanide m-chlorophenyl hydrazone, a potent ionophore and inhibitor of oxidative phosphoryla-
tion that leads to mitochondrial fragmentation; the mitochondrial matrix was visualized via expression of green fluorescent protein (photo: John Rooney).
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responsible for all mtDNA replication and repair, cause a wide 
range of mitochondrial diseases including progressive external 
ophthalmoplegia, Alper’s syndrome, and Leigh’s syndrome 
(Copeland, 2012). The disease Friedreich’s ataxia is caused by 
mutations in the gene encoding frataxin, a protein involved in 
iron-sulfur cluster assembly (Marmolino, 2011).
Although individually rare, diseases caused by mtDNA and 
nDNA mutations are estimated to collectively have an inci-
dence of ~1/4000 individuals (Chinnery et al., 2004; DiMauro 
and Davidzon, 2005; Howell et  al., 2005; Wallace, 2005). 
There are currently no pharmaceutical cures for any mitochon-
drial disease (Nunnari and Suomalainen, 2012).
Mitochondrial Involvement in Common Diseases: 
Causation Versus Correlation
The diseases described above are unambiguously caused by 
mitochondrial dysfunction. There are also many very common 
diseases for which there is strong correlative evidence, suggest-
ing that mitochondrial dysfunction is at least partially causa-
tive (Wallace, 2005). These are frequently diseases of old age 
or energy homeostasis and include neurodegenerative diseases 
such as Parkinson’s Disease and Alzheimer’s Disease (Coskun 
et  al., 2012), many cancers (Brandon et  al., 2006; Kulawiec 
et al., 2010; Penta et al., 2001), diabetes (Rolo and Palmeira, 
2006), metabolic syndrome (Mercer et al., 2010), cardiovascu-
lar disease (Ballinger, 2005), and others (Schon et al., 2012). 
Considerable effort is currently devoted to investigate whether 
these relationships are causal. There is experimental evidence 
demonstrating that defective mtDNA replication and repair 
can accelerate organismal aging (Bratic and Larsson, 2013; 
Trifunovic et al., 2004).
Gene-Environment Interactions
In addition to the genetic diseases described so far, several 
gene-environment interactions have been identified (Cohen, 
2010; Finsterer and Segall, 2010). For example, valproic acid is 
fatal in the context of some mitochondrial diseases (Krähenbühl 
et al., 2000; Silva et al., 2008), aminoglycosides (e.g., genta-
mycin) can cause deafness in the context of specific mtDNA 
mutations (Guan, 2011), and cigarette smoking and alcohol 
intake are major risk factors for vision loss in people who are 
homoplasmic for a mutation causing Leber’s hereditary optic 
neuropathy (Kirkman et al., 2009).
Lessons from Mitochondrial Diseases
The existence of so many mitochondrial diseases illustrates 
the critical importance of maintenance of mitochondrial and 
mtDNA integrity for health. It also raises an important ques-
tion with implications for environment-mediated mitochondrial 
toxicity: Why did it take us so long to realize that many dis-
eases are in fact mitochondrial diseases? Part of the answer is 
surely that these diseases are very complicated. Although they 
often target tissues that have high energy use or contain non-
replicating (and therefore irreplaceable) cells, this is somewhat 
oversimplified (Vafai and Mootha, 2012), and there is signifi-
cant variability in their presentation. Some mtDNA mutations 
result in single-tissue diseases, others affect a wide spectrum of 
tissues, and others affect different tissues in different patients, 
with varying age of onset (Vafai and Mootha, 2012; Nunnari 
and Suomalainen, 2012). Furthermore, as illustrated by the 
valproic acid and aminoglycoside examples, the same environ-
mental exposure may be innocuous in some people but deadly 
in others, depending on genetic background. These complica-
tions suggest that identifying the etiology of an environmentally 
induced mitochondrial dysfunction is likely to be challenging 
with both laboratory and epidemiological approaches, as borne 
out by the observation that, currently, the causes of only ~50% 
of severe cases of mitochondrial dysfunction are identified 
(Vafai and Mootha, 2012).
Drug-iNDucED MitochoNDriAl AND MtDNA 
toxicity
Drugs Can Cause Many Off-Target Mitochondrial Effects
Recognition that mitochondrial toxicity is a key “off-target” 
effect of many drugs is also a relatively recent development. 
Drugs have now been identified that inhibit and uncouple the 
ETC; inhibit mitochondrial transport pathways, fatty acid oxi-
dation or uptake, the citric acid cycle, mtDNA replication, and 
mitochondrial protein synthesis (a common mode of toxicity of 
antibiotics that target bacterial ribosomes, to which mitochon-
drial ribosomes are similar due to mitochondria’s evolution-
ary origins); generate (or exacerbate generation of) ROS; and 
more (Begriche et al., 2011; Cohen, 2010; Dykens and Will, 
2007; Kovacic et al., 2005; Mehta et al., 2008; Neustadt and 
Pieczenik, 2008; Pacheu-Grau et al., 2010; Rowe et al., 2001).
One well-studied example is adriamycin (doxorubicin), a 
chemotherapeutic whose clinical use is limited by the fact that it 
also causes irreversible and cumulative cardiomyopathy (Wallace, 
2007). It appears to act largely by poisoning mitochondria, both via 
redox cycling to generate ROS and by inhibiting ATP production 
via uncoupling of oxidative phosphorylation. Although its 
antineoplastic function is largely a result of DNA intercalation 
and topoisomerase II inhibition in the nucleus, a substantial 
amount reaches mitochondria, where it has a high binding affinity 
for cardiolipin, a lipid found only in the mitochondrial inner 
membrane (Mustonen and Kinnunen, 1993).
Another example is the nucleoside reverse transcriptase 
inhibitors (NRTIs) that are used to combat human immuno-
deficiency virus (HIV) infection. NRTIs act by inhibiting the 
reverse transcriptase activity required for viral replication. They 
have been highly successful in treating adults and in preventing 
transmission of HIV from pregnant mothers to their children, but 
unfortunately many NRTIs also inhibit the mtDNA polymerase 
γ. This has resulted mtDNA depletion- and mutation-mediated 
mitochondrial toxicity, and even death, in patients and in animal 
models (Benhammou et al., 2007; Blanche et al., 1999; Chan, 
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2007; Claessens et  al., 2003; Divi et  al., 2010; Kohler and 
Lewis, 2007). Similar effects have been observed with nucle-
oside analogs intended for other viruses as well (McKenzie 
et al., 1995). Thus, chemicals that damage mtDNA or alter its 
copy number can have very serious health consequences.
Such toxicities have led to failed clinical trials, “Black Box” 
warnings and withdrawal of drugs from the market, and have 
driven the pharmaceutical industry to develop better meth-
ods for detection of drug-induced mitochondrial dysfunction 
(Begriche et al., 2011; Dykens et al., 2007; Marroquin et al., 
2007; Nadanaciva et al., 2009; Pereira et al., 2009).
Lessons from Drug-Induced Mitochondrial Toxicity
Mechanisms of drug-induced toxicity offer lessons in terms 
of how other chemicals might damage mitochondria; these are 
discussed at more length below. As in the case of mitochondrial 
diseases, it is instructive to consider why it took us so long 
to realize that many drugs target mitochondria. One reason is 
that frequently only a small percentage of people have adverse 
reactions (Dykens and Will, 2007). For example, only ~1% of 
children of HIV-treated mothers showed mitochondrial toxic-
ity (Barret et al., 2003). The reason for this variability is not 
entirely clear. In some cases, gene-environment interactions 
are likely the explanation. In others, environment-environment 
interactions, epigenetic factors (see below), or the stochastic-
ity associated with mtDNA replication and allocation may be 
involved. In any case, it is sobering from an environmental toxi-
cology perspective that it took years to recognize the mitochon-
drial toxicity of many drugs because drugs are in general much 
better studied for toxicity than most environmental contami-
nants. This suggests that many environmental pollutants may 
be undiscovered mitochondrial toxicants.
rEAsoNs For MitochoNDriAl VulNErAbility, 
AND FActors thAt MAy MoDulAtE 
VulNErAbility
Reasons for mitochondrial vulnerability are presented graph-
ically in Figure 2 and discussed in more detail below.
Fig. 2. Factors that affect mitochondrial vulnerability to environmental toxicants, as discussed in the text.
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Accumulation of Pollutants
The high lipid content of mitochondrial membranes facilitates 
accumulation of lipophilic compounds such as polycyclic aro-
matic hydrocarbons (PAHs) (Backer and Weinstein, 1982) and 
some alkylating agents (Wunderlich et al., 1972). Cationic metals, 
such as lead, cadmium, mercury, and manganese, have also been 
shown to accumulate in mitochondria preferentially (Atchison and 
Hare, 1994; Bucio et al., 1999; Castellino and Aloj, 1969; Gavin 
et al., 1992; Sokolova et al., 2005a). These metals may accumu-
late in mitochondria due to both entry via calcium transporters 
(i.e., molecular mimicry) and chemical behavior resulting from 
their interactions with mitochondrial pH and charge. The matrix 
has a negative charge and slightly alkaline pH (~8 vs. ~6.9 for 
the intermembrane space) due to the proton pumping associated 
with oxidative phosphorylation. This also results in accumulation 
of certain organic chemicals, particularly amphiphilic xenobiotics 
including well-known mitochondrial toxicants such as ethidium 
bromide, paraquat, 1-methyl-4-phenylpyridinium (MPP+), and 
others (Cohen, 2010; Mehta et  al., 2008). It is also a property 
that is exploited to target toxic (Modica-Napolitano and Aprille, 
2001), diagnostic (Ross et  al., 2005), or therapeutic (Murphy, 
2008; Murphy and Smith, 2007) chemicals to mitochondria.
Ability to Metabolically Activate Pollutants
Another factor contributing to the mitochondrial susceptibil-
ity is the presence of cytochrome P450s in mitochondria, which 
can activate chemicals that are relatively nonreactive prior to 
metabolism, such as PAHs and mycotoxins (Dong et al., 2009; 
Genter et al., 2006; Omura, 2006). In addition, the existence 
of close contacts between mitochondria and the endoplasmic 
reticulum (de Brito and Scorrano, 2010) raises the possibility 
that metabolites generated in the endoplasmic reticulum could 
reach the mitochondria.
mtDNA Exhibits Unique Vulnerabilities But May Be 
Buffered by High Copy Number
mtDNA is more vulnerable than nDNA to some 
environmental genotoxins although the opposite is also true 
in some cases (see below). A number of explanations for this 
observation have been presented, including mtDNA’s physical 
location, its reduced protein packaging compared with nDNA, 
and its reduced repair capacity. These, along with the potential 
for protection due to high copy number, are described in more 
detail below.
Physically, mtDNA nucleoids are anchored to the matrix side 
of the inner membrane, in close proximity to the ETC and many 
proteins that contain transition metal ions. The ETC normally 
generates a significant amount of ROS by electron loss; this has 
been estimated at ~0.1% of O
2
 converted to superoxide anion 
(Beckman and Ames, 1998; Fridovich, 2004) although the 
amount may decrease with mild uncoupling (Miwa and Brand, 
2003). Much of this appears to be produced by Complex I, with 
release to the matrix, and Complex III, with release to the matrix 
and intermembrane space (Brand et  al., 2004). Manganese 
superoxide dismutase (SOD) in the matrix, and copper-zinc 
SOD in the intermembrane space, convert superoxide anion to 
the longer lived and uncharged hydrogen peroxide; additional 
antioxidant enzymes are present and regulated as well (Valle 
et  al., 2005). Mitochondrial H
2
O
2
 may interact with nearby 
metals to produce hydroxyl radicals (Giulivi et  al., 1995) in 
close proximity to mtDNA. The many chemicals, disease states, 
etc., that cause an increase in ROS generation may increase the 
amount of superoxide produced: This includes redox cycling 
agents that can intercept electrons such as adriamycin; inhibi-
tors of the ETC such as antimycin A  and sodium azide that 
lead to a super-reduced state of upstream complexes, increasing 
the tendency to release electrons; dietary and exercise-related 
ETC dysfunction; hyperoxia and hypoxia-reoxygenation; and 
others (Bailey et al., 2006; Barrett et al., 2004; Begriche et al., 
2006; Davies and Doroshow, 1986; Hasegawa et al., 1990; Indo 
et al., 2007; Ishiguro et al., 2001; Li et al., 2003a; Powell and 
Jackson, 2003; Senft et al., 2002a, b; Turrens et al., 1982a, b). 
Furthermore, the Fenton reaction may be facilitated by redox 
cycling of transition metal ions that are either chelated (Dean 
and Nicholson, 1994) or released via ROS-induced degradation 
of metal-containing proteins (Mladenka et al., 2006).
mtDNA lacks histones, which has frequently been cited as 
a potential reason for increased vulnerability. However, recent 
work (Bogenhagen, 2012) has shown that in fact a large number 
of proteins associate with mtDNA, some of which are explicitly 
protective (Valle et  al., 2005), so mtDNA vulnerability to 
reactive chemicals due to “nakedness” may be less than 
previously speculated. Recent work has shown that nucleoid 
structure is not static but can also be remodeled in response 
to exposure to DNA intercalators including ethidium bromide 
and doxorubicin (Ashley and Poulton, 2009a, b) and oxidative 
stress (Rebelo et  al., 2009). Rebelo et  al. (2009) presented 
evidence suggesting that different areas of the mitochondrial 
genome were differentially packaged, so different regions may 
be more or less “naked.” The nucleoid remodeling observed 
by Ashley and Poulton (2009a) was protective against mtDNA 
depletion that resulted from intercalator exposure. Furthermore, 
the remodeling was p53 mediated, increasing the evidence for 
a role of p53 in mitochondrial homeostasis (Szczepanek et al., 
2012). mtDNA occurs in a surprising array of structures in 
cells from a wide range of tissues and species (Kolesar et al., 
2012). This may reflect to some extent significant variation in 
the packaging function of proteins such as Tfam (Campbell 
et  al., 2012) and the transcriptional status of the individual 
genomes (Kolesar et  al., 2012). Finally, Chen et  al. (2005) 
showed that aconitase is a nucleoid component that assists in 
mtDNA maintenance and protection against ethidium bromide 
exposure, raising the possibility that nucleoid repackaging 
may respond to bioenergetics and redox perturbations via 
aconitase mobilization (Shadel, 2005). Thus, mtDNAs likely 
have differential susceptibility to damage, both in a cell type–
specific fashion and even within single cells.
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A very large difference between nDNA and mtDNA is the 
relative lack of repair pathways present in mitochondria, at 
least in humans (there is species variability). Although our 
understanding of mtDNA repair pathways is evolving and 
includes more proteins and pathways than previously recog-
nized (Croteau et al., 2012; Kamenisch et al., 2010; Liu and 
Demple, 2010; Scheibye-Knudsen et al., 2012; Sykora et al., 
2011; Valentin-Vega et al., 2012), many types of damage are 
either irreparable or only very slowly repaired. Base excision 
repair is present in mitochondria, but nucleotide excision repair 
(NER) is not, and recombinational and mismatch repairs are 
either absent or quite limited (Druzhyna et al., 2008; Gredilla 
et  al., 2010; Kazak et  al., 2012; Kraytsberg et  al., 2004). 
Furthermore, mtDNA is a major target for oxidative stress 
(Van Houten et al., 2006), despite the relatively robust capac-
ity for repair of oxidative damage. The sole replicative mtDNA 
polymerase, DNA polymerase γ, appears to have very little 
translesion synthesis capacity (Graziewicz et al., 2004, 2007; 
Kasiviswanathan et  al., 2012), so that this damage tolerance 
mechanism is also lacking or very limited. The absence of NER 
is of particular relevance from an environmental toxicology 
perspective because it means that many important environmen-
tal genotoxicants including some PAHs, mycotoxins, and ultra-
violet light will cause damage that is irreparable in mtDNA. 
Furthermore, because a subset of DNA damage caused by ROS 
is repaired by NER (Brooks, 2008; Cline et al., 2010), any of 
the many factors that increase ROS in mitochondria (see above) 
could also create some highly persistent damage.
What might the effects of persistent mtDNA damage be? In 
addition to inhibiting replication, there is strong evidence that 
such damage inhibits RNA transcription (Cline, 2012) and mito-
chondrial function (Bess et al., 2012; Brar et al., 2012; Furda 
et al., 2012b; Leung et al., 2013; Rachek et al., 2009). Although 
most of the measures of mitochondrial function so far have 
focused on energetics (ATP levels, oxygen consumption, etc.), 
it may be useful to consider other endpoints. For example, might 
mitochondrial dysfunction in the context of steroid-producing 
cells result in endocrine disruption? mtDNA damage likely con-
tributes to generation of mtDNA mutations although this pro-
cess is currently poorly understood (Copeland, 2012; Krishnan 
et al., 2008; Kulawiec et al., 2010; Loeb et al., 2005). Improved 
sequencing methods support the relatively high (compared with 
the rest of the mtDNA) mutability of the D loop region (Schmitt 
et  al., 2012) and will improve our understanding of both 
mutagenesis and normal occurrence of heteroplasmy, which is 
now detectable at much lower levels than previous methods per-
mitted. The “vicious cycle” hypothesis suggests that mitochon-
drial damage can lead to greater mitochondrial dysfunction, in 
turn leading to greater release of ROS and damage, etc. (Yakes 
and Van Houten, 1997).
On the other hand, the mitochondrial genome is present in 
multiple copies, potentially conferring buffering via redundancy. 
As described earlier, mitochondrial dysfunction resulting from 
mtDNA mutations is not observed until a certain threshold of 
heteroplasmy is reached. This likely results from the combination 
of multiple copies and the fact that mitochondrial fusion permits 
swapping of contents, sometimes referred to as complementation 
or functional buffering. Presumably, such buffering would also 
occur for mtDNA damage. We recently found that similar levels 
of mtDNA damage led to much greater inhibition of mitochon-
drial function in live Caenorhabditis elegans than cells in culture 
(Bess et al., 2012, 2013b; Leung et al., 2013). Although there are 
multiple possible explanations for this observation, it could result 
from the much higher mtDNA copy number in human cells in 
culture compared with C. elegans. The high copy number also 
means that irreparable—or even repairable—DNA damage can 
be handled by degrading damaged mtDNAs by one of a number 
of possible mechanisms including degradation of the genomes 
themselves or of entire mitochondria along with mtDNA (i.e., 
autophagy or mitophagy)(Bess et  al., 2012, 2013a, b; Rouzier 
et al., 2012; Shokolenko et al., 2009). mtDNAs that have been 
removed can then be replaced by mtDNA replication. The high 
copy number and potential functional buffering also suggests that 
mtDNA damage may be an excellent early biomarker of mito-
chondrial damage: High levels of mtDNA damage will occur and 
persist and therefore be detectable, yet will precede late-stage col-
lapse of mitochondrial function associated with clinical detection.
Further complicating the picture is evidence that inhibition 
of mitochondrial function may, at intermediate levels and under 
some circumstances, have at least some beneficial effects. For 
example, mild inhibition of mitochondrial function extends 
lifespan and increases resistance to a variety of stressors in 
C. elegans (Dillin et al., 2002; Rea et al., 2007) and mice (Liu 
et al., 2005). In many cases, this effect is only observed if the 
inhibition occurs during development and not if it occurs later in 
life. However, it is important to note that greater inhibition leads 
to pathological effects, and in general, developmental exposures 
that alter programming of mitochondrial function later in life 
are not always be beneficial (Knudsen and Green, 2004).
Cell Type Modulates Sensitivity
Mitochondria vary dramatically from tissue to tissue (Calvo 
and Mootha, 2010; Vafai and Mootha, 2012), so it is not surpris-
ing that evidences from mitochondrial disease and mitochondrial 
drug toxicity indicate that different cell types are differentially 
susceptible to mitochondrial toxicants. There are many factors 
that may sensitize specific cell types to mitochondrial toxic-
ity. For example, high reliance on mitochondrial function may 
mean that dysfunction more easily causes cell death (e.g., as 
often seen in mitochondrial diseases that target high energy-use 
cells) because the increased function may result in higher ROS 
production in some circumstances. An interesting example here 
is the aforementioned case of adriamycin, which causes princi-
pally mitochondrial toxicity in heart, where much electron flow 
occurs in mitochondria, and much more endoplasmic reticulum 
damage in liver, where electron flow is much higher in the ER 
(Berthiaume and Wallace, 2007; Brown and Borutaite, 2012). 
Certain cell types (e.g., some neurons) also have low antioxidant 
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defenses and/or high inherent oxidative stress (Crouch et  al., 
2007). Proliferating cells, both cancerous and noncancerous, 
generate a great deal of ATP via aerobic glycolysis rather than 
oxidative phosphorylation, apparently in order to preferen-
tially utilize carbon for biosynthesis required for cell division 
(Vander Heiden et  al., 2009). Any functional deficits associ-
ated with mitochondrial dysfunction in such cells may result 
more from loss of biosynthetic than energy-generating capac-
ity. Finally, there is evidence that mtDNA repair capacity varies 
with cell type, with brain tissue in particular showing low repair 
(Karahalil et al., 2002; Szczesny et al., 2010). Nonetheless, it 
is clear that the full spectrum of factors that result in cell-type 
sensitivity is not well understood, and short-term effects may 
differ from long-term effects, in part due to the occurrence of 
secondary responses (Vafai and Mootha, 2012).
Developmental Stage Modulates Sensitivity
Some developmental stages are likely more sensitive to 
mitochondrial toxicants due to age-dependent differences in 
mitochondrial content, mitochondrial metabolism, and mito-
chondrial defense/repair mechanisms.
Mitochondrial count/volume and mtDNA copy number vary 
dramatically with age in humans and other species that have 
been examined. Although most cells thus far examined have 
103–104 copies of mtDNA, somatic and primordial germ cells 
in the early embryo may contain as few as 10s or 100s of cop-
ies, constituting a “bottleneck” in mtDNA copy number and/
or transferral (Carling et al., 2011; Jansen, 2000; Jansen and de 
Boer, 1998; Pikó and Taylor, 1987; Shoubridge and Wai, 2007). 
Lower copy number is likely to reduce the protective effect of 
redundant copies described above. However, the bottleneck 
may also offer an opportunity for removal of severely damaged 
mitochondria or aberrant mtDNAs (Fan et  al., 2008; Stewart 
et al., 2008), although it is not entirely clear when this process 
of purifying selection acts or how it may vary by mutation type 
(Freyer et al., 2012), in part because the mitochondrial genome 
is not believed to be very active early in development when the 
bottleneck occurs. Furthermore, although newly fertilized eggs 
have a very high mtDNA copy number (~105 (Shoubridge and 
Wai, 2007); but highly variable (May-Panloup et  al., 2007)), 
the evidence suggests that in many species those mtDNAs are 
simply allocated into daughter cells during early development, 
without additional replication, resulting in much lower copy 
number after initial rounds of cell division (Artuso et al., 2012; 
Bratic et al., 2009; Chase and Dawid, 1972; Leung et al., 2013; 
Rubenstein et  al., 1977; Tsang and Lemire, 2002; Wai et  al., 
2008). Because mtDNA allocation into daughter cells at mitosis 
(“mitotic segregation”) is apparently random, and the bottleneck 
phenomenon results in low copy number at least in some cell 
types (most have not been examined), it is possible for some 
cells to end up with a high percentage of damaged or mutant 
mtDNAs after multiple cycles of cell division. This high level of 
heteroplasmy or damaged mtDNAs would then be inherited by 
all of the cells derived from the progenitor cell. As previously 
pointed out in other contexts (Krishnan et al., 2008), mitochon-
drial alterations such as mutations in cell types that do undergo 
a bottleneck would not manifest until the second (in the case of 
somatic cells) or even third (in the case of primordial germ cells) 
generation, relative to an exposed mother. The effects might be 
somatic alterations or fertility difficulties in the children of the 
exposed mother or mitochondrial defects in the grandchildren. 
There is also a lower copy number in old age (Hebert et  al., 
2010; Meyer et  al., 2007), suggesting vulnerability in aged 
individuals.
Age-related changes in mitochondrial metabolism are also 
well documented. Early life stages often display more anaerobic 
metabolism and spherical morphologies, and older individuals 
typically show signs of mitochondrial dysfunction although 
these effects are frequently tissue specific (Braeckman et al., 
2002; Brand et al., 2004; Brys et al., 2007, 2010; Dillin et al., 
2002; Hebert et al., 2010; Jansen and de Boer, 1998; Knudsen 
and Green, 2004; Meyer et al., 2007; Tsang and Lemire, 2003; 
Tsang et al., 2001; Yasuda et al., 2006). How reduced aerobic 
mitochondrial function will influence the effect of mitochondrial 
toxicants is not certain. On the one hand, reduced dependence 
on oxidative phosphorylation can result in less sensitivity to 
mitochondrial toxicity, as observed in at least some cells in 
culture (Marroquin et al., 2007). On the other hand, reduced 
capacity to generate energy might inhibit repair processes and 
stress responses. Furthermore, the age dependence of nonenergy-
related mitochondrial functions (calcium homeostasis, heme 
and iron-sulfur cluster assembly, synthesis of pyrimidines and 
steroids, etc.) is less well understood. Finally, there is evidence 
for an age-related decrease in base excision repair capacity in 
mtDNA (Anson et al., 2006; Druzhyna et al., 2008; Gredilla 
et al., 2010; Maynard et al., 2009; Szczesny and Mitra, 2005; 
Szczesny et al., 2003).
We speculate that these early-life vulnerabilities make mito-
chondria important candidates for playing a role in diseases and 
pathologies resulting from early environmental exposures, an 
important area of current environmental health research (Kai 
et al., 2006; Knudsen and Green, 2004; Landrigan et al., 2005). 
Similarly, late-life vulnerabilities suggest that environmental 
toxicants may play an important role in the mitochondrial dys-
function commonly observed in aging and diseases of aging 
(Ames et  al., 1995; Chomyn and Attardi, 2003; Fridovich, 
2004; Melov et al., 1995; Nicholls, 2002).
Conclusion: Vulnerability and Robustness
Many of the physical, chemical, and biological characteris-
tics of mitochondria make them vulnerable to toxicant expo-
sure (Fig.  2). At the same time, mitochondria are generally 
robust (Vafai and Mootha, 2012) and are protected in a num-
ber of ways, including great redundancy of content, ability to 
replace defective components, and complementation. However, 
genetic deficiencies in the mitochondrial processes responsi-
ble for these defenses may sensitize some people to exposures 
(Meyer and Bess, 2012).
 MITOCHONDRIAL TOXICITY 7
MitochoNDriAl suscEptibility to 
ENViroNMENtAl toxicANts
The pathologies associated with mitochondrial disease and 
drug-induced toxicity highlight the importance of mitochondrial 
function for health. The demonstrated mitochondrial effects of 
many drugs along with the theoretical considerations described 
above lead to the concern that mitochondria may be an important 
target for many environmental toxicants, presumably via many 
or all of the same mechanisms described above for drugs. The 
possibility that environmental contaminants may target mito-
chondria has been noted previously (Shaughnessy et al., 2010). 
Nonetheless, which contaminants are important is far from clear 
(Schmidt, 2010). We review some of the literature on pollutants 
that target mitochondria, focusing in particular on mtDNA as a 
target. We also discuss promising research approaches and pro-
pose important directions for future research.
Environmental Mitochondrial Toxicants
Although environmental contaminants have in general been 
less well studied than drugs from the mitochondrial toxicity 
perspective, there are nonetheless some well-understood exam-
ples. Paraquat, for example, appears to act largely by redox 
cycling in a fashion analogous to adriamycin (Martinez and 
Greenamyre, 2012). Rotenone is a Complex I  inhibitor that 
results in increased ROS production, mtDNA damage, and 
apoptosis (Ishiguro et al., 2001; Li et al., 2003b; Shokolenko 
et  al., 2009). Carbon monoxide and cyanide act as Complex 
IV inhibitors (Ninomiya-Tsuji, 2008). An example of an envi-
ronment-environment interaction is provided by the unfortu-
nate co-occurrence of folate deficiency and exposure to either 
cyanide or methanol, which appears to have resulted in mito-
chondrial toxicity–mediated optic neuropathy in ~50,000 peo-
ple (Sadun, 1998). There are also many other contaminants that 
are less well characterized as mitochondrial toxicants but are 
reported to cause at least some of their effects via mitochondrial 
toxicity. These include particulate matter (Janssen et al., 2012; 
Hou et al., 2010; Xia et al., 2004), lipopolysaccharide (Suliman 
et  al., 2003), cadmium and copper (Garceau et  al., 2010; 
Sokolova et al., 2005a, b), PAH quinones (Babu et al., 2005), 
dioxin (Biswas et  al., 2008; Shertzer et  al., 2006), acrolein 
(Jia et al., 2007), acrylamide (Lee et al., 2012), perfluorinated 
compounds (Starkov and Wallace, 2002; Walters et al., 2009), 
usnic acid (Guo et al., 2008; Joseph et al., 2009), methoxychlor 
(Gupta et al., 2006), 3-nitropropionate (Sabri, 1998), cigarette 
smoke (Ballinger et  al., 1996; Cakir et  al., 2007; Westbrook 
et al., 2010), manganese and lead (Bowman et al., 2011; Sabri, 
1998; Zheng et al., 1998), arsenic (Dopp et al., 2008; Echaniz-
Laguna et  al., 2012; Naranmandura et  al., 2011), mercury 
(Belyaeva et al., 2012; Farina et al., 2012; O’Hara et al., 2002), 
and pentachlorophenol (Valmas et al., 2008). It is important to 
note that many if not all of the exposures are likely to affect tar-
gets other than mitochondria, and in some cases, mitochondrial 
effects may be secondary to effects elsewhere.
However, although many of these chemicals cause effects 
other than mitochondrial toxicity, the importance of the mito-
chondrial effects is in some cases supported by the fact that 
there is overlap in the pathologies observed after exposures 
and mitochondrial diseases. For example, the optic neuropa-
thy described by Sadun (1998) was very similar to Leber’s 
Hereditary Optical Neuropathy, and rotenone, paraquat, and 
manganese are all associated with Parkinson’s Disease or 
related symptoms (Cannon and Greenamyre, 2011; Tanner 
et al., 2011).
Environmental Mitochondrial Genotoxicants
Supplementary table  1 lists studies that have directly 
compared nDNA with mtDNA damage after chemical exposure. 
A few studies are included that examined only mtDNA damage 
or deletions. Studies that have examined chemical effects 
on mtDNA copy number only, while important, were too 
numerous to tabulate. Although a full review of the observed 
effects is beyond the scope of this review, it is important to note 
that chemical exposures have resulted in both decreased and 
increased mtDNA copy number, and this may depend not just 
on the chemical but also on the dose and time point assessed. 
For example, oxidative stress appears to be able to stimulate 
mitochondrial biogenesis (including mtDNA replication) at 
low doses but depletion at higher doses. This may be a function 
of competing effects of ROS, resulting in both removal of 
damaged genomes (Shokolenko et  al., 2009) and induction 
of biogenesis (Suliman et  al., 2005). In addition, short-term 
depletion can result in compensatory responses (Suliman et al., 
2003; Leung et al., 2013) over the longer term.
Some genotoxicants cause more damage in mtDNA (e.g., 
PAHs and oxidative stress), whereas others (e.g., methylmeth-
anesulfonate) cause more damage in nDNA (Supplementary 
table 1). In some cases (e.g., cisplatin, aflatoxin B
1
), both have 
been reported (Supplementary table 1). For some toxicants, the 
degree of differential vulnerability has been quite variable in 
different reports. In a dramatic example, PAHs and aflatoxin 
B
1
 have been reported to cause more mtDNA than nDNA dam-
age, but the ratio has been as low as less than 2:1 and as high 
as 500:1 (Supplementary table  1). Similarly, mtDNA:nDNA 
damage ratios after cisplatin exposure have varied from much 
less than 1 to several hundred. The reasons for these large dif-
ferences are unclear but may reflect different experimental 
designs, methods for measuring DNA damage, or cell type dif-
ferences such as nucleoid packaging (Campbell et al., 2012). 
Of note, the number of genotoxicants that have been tested for 
relative mitochondrial versus nuclear genotoxicity is relatively 
limited.
The differential mtDNA versus nDNA susceptibilities likely 
reflect a combination of the different factors reviewed earlier: 
toxicokinetics (i.e., where the contaminant and/or its metabo-
lites compartmentalize within the cell), differential packaging 
of the two genomes, lack of repair of some types of damage in 
mtDNA, etc.
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Approaches for Investigating mtDNA Damage
As can be seen from the examples above, it can be chal-
lenging to determine that a specific chemical causes toxicity 
only via mitochondrial effects. Most chemicals, even those that 
clearly directly cause mitochondrial toxicity, will also cause 
some other effects. In some cases, mitochondrial toxicity may 
be a secondary effect. How then can we isolate the effects of 
mitochondrial or mtDNA toxicity?
Several approaches have been used. One is to remove mtDNA 
from the picture altogether via the use of rho zero (mtDNA-
depleted) cells (Brar et al., 2012; Davermann et al., 2002; Huang 
et  al., 2012). This approach is clean but has the disadvantage 
of creating cells that are highly abnormal. A second approach is 
to create mtDNA damage by targeting a restriction endonucle-
ase to the mitochondria, so that it will only cut mtDNA. This is 
also a clean approach, with the disadvantage that it only permits 
the study of doublestrand breaks, rather than any of the types of 
DNA damage that are more commonly caused by toxicant expo-
sure. A third approach is genetic; for example, Tann et al. (2011) 
recently used siRNA to specifically deplete the mtDNA repair 
enzyme ExoG, Green et al. (2011) studied the effects of p53 defi-
ciency on cellular response to rotenone, and Simsek et al. (2011) 
compared the rescue capacity of nuclear- versus mitochondrial-
targeted DNA Ligase III in DNA Ligase III–deficient mice. 
Several groups have demonstrated mtDNA-mediated effects by 
targeting DNA repair enzymes to mitochondria, improving DNA 
repair, and reducing or rescuing the toxic effects observed (Cai 
et al., 2005; Koczor et al., 2009; Rachek et al., 2009; Shokolenko 
et  al., 2010). The use of a suite of toxicants that all impact a 
similar mitochondrial target (e.g., ETC complex I) has also been 
employed (Kulawiec et al., 2009). Finally, it is possible to use 
a genotoxicant that causes much more damage to mtDNA than 
nDNA (Anson et al., 1998, 2006; Herraiz et al., 2003; Rachek 
et al., 2009; van der Eb et al., 2003) or that is repaired in nDNA 
but not in mtDNA (Bess et al., 2012; Leung et al., 2013). These 
approaches are more environmentally realistic but less clean 
because it is never possible to entirely avoid some damage to 
macromolecules other than mtDNA.
A methodological prerequisite for such studies is an unbiased 
method for comparing DNA damage in the two genomes. One 
approach is to measure specific adducts after extracting and iso-
lating two genomes. However, this may lead to artifacts (Anson 
et al., 2000). An alternative approach is to use a sequence-based 
approach that permits analysis of damage in the two genomes 
without differential extraction. The two best described methods 
are the Southern blot (Anson et al., 2006) and QPCR (Furda 
et al., 2012a; Hunter et al., 2010; Meyer, 2010) assays.
Another critical methodological consideration, especially for 
in vitro (cell culture) work, is ensuring that the cells are actually 
using their mitochondria. Marroquin et al. (2007) showed that 
cells grown on typical high glucose media, which derive nearly 
all of their ATP from anaerobic metabolism, show much less 
susceptibility to a variety of mitochondrial toxicants than do 
the same cells grown on galactose, which forces them to use 
oxidative phosphorylation. This also means that the typical 
concerns about using cancer cells are especially pertinent 
because many cancer cells are not only grown on glucose but 
exhibit very abnormal mitochondrial metabolism in any case 
(Nakajima and Van Houten, 2012).
Future Directions
There are important areas of basic mitochondrial biology 
that are growing rapidly and represent important opportuni-
ties for interdisciplinary research for environmental health 
scientists. For example, the growing understanding of nuclear-
mitochondrial signaling and coordination described earlier has 
important implications for mitochondrial responses to stress-
ors. Three additional emerging research areas are addressed 
briefly below.
Our understanding of repair and removal of mtDNA dam-
age has increased greatly. Nonetheless, much remains to be 
learned about repair pathways per se (Gredilla et  al., 2010; 
Liu and Demple, 2010), how mtDNA damage leads to mtDNA 
mutations (Copeland, 2012; Krishnan et al., 2008; Loeb et al., 
2005), and the role of mitochondrial dynamics in mtDNA 
maintenance. Recent results demonstrate that in addition to 
functioning in removing mtDNA damage (Bess et al., 2012, 
2013a, b; Rouzier et  al., 2012) and mtDNA mutations (Fan 
et al., 2008; Stewart et al., 2008), mitochondrial dynamics pro-
cesses may be critical even for normal function of DNA repair 
pathways that are present in the mitochondria (Rouzier et al., 
2012) and for maintenance of nDNA integrity (Qian et  al., 
2012). As discussed above, a key future area of research will 
be to investigate how these functions vary by cell type and 
developmental stage.
Second, there is growing understanding of the importance 
of epigenetic-mitochondrial interactions (Chinnery et  al., 
2012; Wallace and Fan, 2010). Most directly, there is now evi-
dence for methylation and hydroxymethylation at some CpGs 
in mtDNA, probably carried out via a mitochondrial-targeted 
form of DNA methyltransferase 1 (DNMT1), where it may 
serve as both a de novo and maintenance methyltransferase 
(Shock et al., 2011). Furthermore, the levels of mitochondrial 
DNMT1 were regulated by stress-responsive transcription fac-
tors involved in mitochondrial biogenesis (Shock et al., 2011), 
and one study reports that exposure to metal-rich particulate 
matter can alter mtDNA methylation (Byun et al., in press). It 
will be important to clarify both how common pollutant-medi-
ated alterations in mtDNA methylation are and what the func-
tional consequences of mtDNA methylation are. More indirect 
evidence for a mitochondria-epigenetics relationship was pro-
vided by Carugno et al. (2012), who found in an epidemiologi-
cal study that benzene exposure resulted in increased mtDNA 
copy number, and that this correlated with altered methylation 
patterns in four nuclear loci (LINE-1, Alu, p15, and MAGEA1). 
There are also examples of nuclear-encoded mitochondrial pro-
teins whose epigenetic regulation affects mitochondrial homeo-
stasis and mitochondrial changes affecting nDNA methylation. 
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For example, in vitro methylation of the Tfam promoter site led 
to reduced transcription of mtDNA (Choi et al., 2004); Tfam 
function is absolutely required for mtDNA maintenance and 
mitochondrial function, as shown using various mouse Tfam 
knockout strains (Dogan and Trifunovic, 2011). Methylation 
of the mtDNA polymerase γ regulates mtDNA copy number 
(Kelly et al., 2012). Loss of mtDNA altered nDNA methylation 
at multiple specific loci in cancer cell lines (Smiraglia et al., 
2008; Xie et  al., 2007). The mechanisms for mitochondrial-
nuclear influences are unclear but may include retrograde 
signaling (Bungard et al., 2010), oxidative stress–induced alter-
ations in DNA methylation (Chia et al., 2011), and alterations 
in mitochondrial function that reduce availability of mitochon-
dria-produced molecules required and potentially rate limit-
ing for epigenetic modification (e.g., methyl groups for DNA 
methylation or cofactors such as flavin adenine dinucleotide, 
NAD+, acetyl-CoA, and α-ketoglutarate required for histone 
modification; Cyr and Domann, 2011; Donohue and Bultman, 
2012; Minocherhomji et al., 2012).
Finally, in addition to laboratory work, we hope that epide-
miologists will consider mitochondrial endpoints. Although 
there are diseases where we know mitochondrial dysfunction 
is causal, more research is needed for many more where there 
is only correlative evidence or where such association may be 
theoretical only. Epidemiological work may be particularly dif-
ficult in the context of mitochondrial dysfunction for a variety 
of reasons, including (1) the unusual patterns of heritability, (2) 
heteroplasmy and the requirement that a threshold be reached 
prior to clinical detection of effects, (3) the potential for latency 
of effects, especially when a damaging event occurs early in 
development, and (4) potential epigenetic influences.
In conclusion, we argue that mitochondria are likely an under-
appreciated target of environmental contaminants and hope that 
future work from the environmental toxicology and environ-
mental health communities will focus more on mitochondria.
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